Buprenorphine (Brixadi® & Sublocade®) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Brixadi and Sublocade (buprenorphine extended‑release injections) only for treatment of moderate‑to‑severe opioid use disorder (explicitly excluded for pain management), with initial and continuation authorizations limited to no more than 12 months each. Coverage requires either prior maintenance buprenorphine or a tolerated buprenorphine test dose, dosing per FDA labeling, administration/dispensing in REMS‑certified settings/providers, documentation of diagnosis and REMS compliance, counseling/psychosocial support, and evidence of clinical benefit for continuation.

"Continuation of therapy: Brixadi or Sublocade dosing is in accordance with the U."

Sign up to see full coverage criteria, indications, and limitations.